Subtype
Neuroblastic Tumor
CI-CAN-00001274Explore in graph →
137 active trials3 approved drugs28 evidence items
- NCIt
- C6963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001274Explore in graph →
Clinical trials
619 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 |
| clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT00996710 | Genomic Structural Variation in Cancer Susceptibility | active not recruiting | — | 1,275 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT07223606 | Fecal Microbiota Transplant for Neuroblastoma in a Single Patient | no longer available | — | — | ProgenaBiomeOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04385277 | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | active not recruiting | Phase 2 | 41 | Children's Oncology GroupNETWORK | 4 | Oct 27, 2025 | clinicaltrials |
| NCT02605421 | Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma | recruiting | Phase 2 | 12 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT00588068 | Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome | recruiting | — | 2,070 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT05429502 | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | terminated | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 10, 2025 | clinicaltrials |
| NCT03033303 | A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma | completed | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02245997 | Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma | completed | Early Phase 1 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07195500 | Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma | recruiting | — | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT03294954 | GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma(GINAKIT2) | recruiting | Phase 1 | 70 | Baylor College of MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04023331 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma | terminated | Phase 1 / Phase 2 | 21 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03107988 | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) | completed | Phase 1 | 65 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 4 | Sep 15, 2025 | clinicaltrials |
| NCT06798532 | Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic Tumors(AKA-NBL) | not yet recruiting | — | 150 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07111117 | Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.(NEUROBLASTOTEP) | not yet recruiting | Phase 2 | 30 | Institut CurieOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07141862 | Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method(PREFERPUBER) | recruiting | — | 89 | University Hospital, Clermont-FerrandOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05135975 | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | recruiting | Phase 2 | 86 | Nationwide Children's HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05012098 | Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06852807 | 18F-mFBG PET Imaging in the Evaluation of Neuroblastoma | recruiting | — | 200 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02650648 | Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | completed | Phase 1 | 85 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07067346 | Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma | recruiting | Early Phase 1 | 10 | Sichuan UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07090538 | GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma. | not yet recruiting | Early Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06872489 | Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors | available | — | — | Second Life TherapeuticsINDUSTRY | 0 | Jul 23, 2025 | clinicaltrials |
| NCT05192980 | SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours(BIOPORTAL) | recruiting | N/A | 600 | Institut CurieOTHER | 4 | Jul 22, 2025 | clinicaltrials |
| NCT07064746 | Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma(MIBG & SSTR NB) | recruiting | — | 150 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06485947 | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma(DBPilot) | recruiting | Phase 1 | 38 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT00703222 | A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells(CHESAT) | completed | Phase 1 / Phase 2 | 7 | Baylor College of MedicineOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06013618 | Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma | recruiting | Phase 2 | 120 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT03503864 | Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma | active not recruiting | Phase 2 | 80 | Yang LiOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06703944 | Risk Model for Metastasis Detection of Neuroblastoma(NB) | enrolling by invitation | — | 500 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02378428 | MIBG Therapy for Patients With MIBG Avid Tumors(MIBG) | active not recruiting | Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT00898755 | Collecting and Storing Tissue From Young Patients With Cancer | completed | — | 213 | Children's Oncology GroupNETWORK | 2 | May 2, 2025 | clinicaltrials |
| NCT06948994 | A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma | not yet recruiting | Phase 1 / Phase 2 | 15 | Guangzhou Women and Children's Medical CenterOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT06933394 | Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma | recruiting | Phase 2 | 92 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT03332667 | MIBG With Dinutuximab +/- Vorinostat | completed | Phase 1 | 45 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06674265 | Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma | recruiting | Phase 1 | 10 | Marzieh EbrahimiINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors(STIR) | terminated | Phase 2 | 15 | Monica ThakarOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03496402 | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)(MICCHADO) | active not recruiting | N/A | 600 | Institut CurieOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06873672 | Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China | not yet recruiting | — | 360 | RenJi HospitalOTHER | 1 | Mar 13, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Nov 24, 2025source: clinicaltrials